A retrospective study to evaluate the effectiveness of Oritavancin in patients with Acute bacterial skin and skin structure infections : A real world data

Trial Profile

A retrospective study to evaluate the effectiveness of Oritavancin in patients with Acute bacterial skin and skin structure infections : A real world data

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Oritavancin (Primary) ; Dalbavancin; Daptomycin; Vancomycin
  • Indications Bacterial infections; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Mar 2017 Primary endpoint (Success (cured or improved) at 5-30 days after the course of antibiotic therapy has been completed) has been met, according to the results published in the Infectious Diseases and Therapy
    • 01 Mar 2017 Results published in the Infectious Diseases and Therapy
    • 29 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top